2 enrolling by invitation. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Enrolling by invitation 2 |
Follow Michael Pulsipher: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions - Acute Myeloid Leukemia | Phase 2 | Enrolling by invitation | Michael Pulsipher | 30 | 2021-08-24 | 2025-05-04 |
| KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children CliniMacs TCR alpha-beta-Biotin system - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Enrolling by invitation | Michael Pulsipher | 50 | 2015-10-01 | 2025-05-04 |
Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
United States (2)